This activity is made possible by an unrestricted educational grant from Pfizer , New York, New York, and is based on a meeting held on September 4, 2008, and subsequent
discussions among the authors through March 18, 2010.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Gossel TA. OTC NSAIDs: New Considerations and Options in Treating Osteoarthritis Pain in the Pharmacy Setting. New Hyde Park, New York: The CE Solution.
- Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper.Arthritis Rheum. 2008; 59: 1058-1073
- Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study.Am J Med. 2006; 119: 255-266
- The synovial prostaglandin system in chronic inflammatory arthritis: differential effects of sterioidal and nonsterioidal anti-inflammatory drugs.Br J Pharmacol. 1981; 73: 893-901
- Properties and actions of non-steroidal anti-inflammatory drugs, including their effects on prostaglandin and macromolecular synthesis.Prostaglandins Leukot Essent Fatty Acids. 1988; 33: 239-252
- An evidence-based review of the cardiovascular risks of nonstreroidal anti-inflammatory drugs.Am J Cardiol. 2009; 103: 1227-1237
- The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers.Am J Cardiol. 2008; 101: 1060-1063
- Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.Circulation. 2007; 115: 3156-3164
- Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs.Gastroenterol Clin North Am. 2009; 38: 305-314
- Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association.Circulation. 2007; 115: 1634-1642
- Analgesic-antipyretic agents: pharmacotherapy of gout.in: Brunton L.L. Lazo J.S. Parker K.L. The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill, New York, New York2006: 671-715
- Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population.Am J Kidney Dis. 2005; 45: 531-539
- Review of potential risk factors for kidney (renal cell) cancer.Semin Urol Oncol. 2001; 19: 280-293
- Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high risk subgroups and time course of risk.Arthritis Rheum. 2006; 54: 1378-1389
- Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.Lancet. 2005; 365: 475-481
- Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.Arch Intern Med. 2008; 168: 1219-1224
- Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.N Engl J Med. 2000; 343: 1520-1528
- The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.Ann Intern Med. 2005; 142: 481-489
- Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.N Engl J Med. 2007; 357: 360-369
- Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.Lancet. 2004; 363: 1751-1756
- Basic biology and clinical application of specific cyclooxygenase-2 inhibitors.Arthritis Rheum. 2000; 43: 4-13
- Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial.JAMA. 2000; 284: 1247-1255
- Collaborative overview of randomized trials of antiplatelet treatment.BMJ. 1994; 308: 81-106
- An update on aspirin in the primary prevention of cardiovascular disease.Arch Intern Med. 2003; 163: 2006-2010
- Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.N Engl J Med. 2001; 345: 1809-1817
- The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.Gastroenterology. 2008; 134: 937-944
- Covalent binding of radioactivity from 14 C rofecoxib, but not 14 C celecoxib or 14 C CS-706, to the arterial elastic of rats.JPET. 2006; 34: 1417-1422
- Mechanism for covalent binding of rofecoxib to elastin of rat aorta.JPET. 2007; 320: 1195-1203
- Celecoxib decreases endothelial tissue factor expression through inhibition of c-jun terminal NH 2 kinase phosphorylation.Circulation. 2005; 111: 1685-1689
- COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.Proc Natl Acad Sci U S A. 2002; 99: 13926-13931
- Mechanism of action of acetaminophen: is there a cyclooxygenase 3?.Clin Infect Dis. 2000; 31: 8202-8210
- Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol).Nature (London). 1972; 240: 410-411
- COX-2 selective inhibitors in the treatment of osteoarthritis.Semin Arthritis Rheum. 2007; 38: 165-187
- Conversion of acetaminophen to the bioactive N-acyphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic conjunction in the nervous system.J Biol Chem. 2005; 280: 21405-21412
- Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.Circulation. 2006; 114: 1028-1035
- Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.N Engl J Med. 2005; 352: 1071-1080
- Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT).PLoS Clin Trials. 2006; 1: e33
- Osteoarthritis: simple analgesics versus nonsteroidal anti-inflammatory drugs.J Rheumatol. 2001; 28: 932-934
- Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.N Engl J Med. 2005; 352: 1092-1102
- Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users.Arch Intern Med. 2004; 164: 1243-1246
- Cardiovascular morbidity and mortality in women associated with rheumatoid arthritis.Circulation. 2003; 107: 1303-1307
- Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.BMJ. 2005; 330 (1366–1342)
- Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-Term (MEDAL) programme: a randomised comparison.Lancet. 2006; 368: 1771-1781
- Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.Lancet. 2004; 364: 675-684
- Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke.Stroke. 2008; 39: 2037-2045
- Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-control study.Stroke. 2003; 34: 379-386
- Defining the problem of treating the patient with hypertension and arthritis pain.Am J Med. 2009; 122: S3-S9
- Renal syndromes associated with nonsteroidal antiinflammatory drugs.N Engl J Med. 1984; 310: 563-572
- Nonsteroidal anti-inflammatory drugs: effects on kidney function.J Clin Pharmacol. 1991; 31: 588-598
- Arachidonic acid metabolites and the kidney.in: Brenner B.M. Brenner and Rector's The Kidney. 7th ed. W. B. Saunders, St. Louis, Missouri2004: 727-761
- Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure.Q J Med. 1995; 88: 551-557
- Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure.Arch Intern Med. 1996; 156: 2433-2439
- Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons.Am J Epidemiol. 2000; 151: 488-496
- Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.Circulation. 2003; 108: 2308-2311
- Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis.Am J Cardiol. 2002; 90: 959-963
- Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis.Am J Cardiol. 2009; 104: 840-845
- Increased mortality and cardiovascular mortality associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure.Arch Intern Med. 2009; 169: 141-149
- Effects of celecoxib and naproxen on renal function in the elderly.Arch Intern Med. 2000; 160: 1465-1470
- Changes in renal function with aging.Clin Geriatr Med. 1998; 14: 199-209
- Anti-inflammatory agents and renal function.Semin Arthritis Rheum. 2002; 32: S33-S42
- Epidemiology and etiology of premalignant and malignant urothelial changes.Scand J Urol Nephrol Suppl. 2000; 205: 105-115
- Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib, and acetaminophen (paracetamol).Curr Pharm Des. 2002; 2: 1063-1075
- Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.JAMA. 2006; 296: 1619-1632
- Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs.Lancet. 1994; 343: 769-772
- Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.Circulation. 1997; 96: 2751-2753
- Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.Ann Intern Med. 2009; 150: 396-404
- Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.Ann Intern Med. 2009; 150: 405-410
- The coxibs, selective inhibitors of cyclooxygenase-2.N Engl J Med. 2001; 345: 433-442
- Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen?.Basic Clin Pharmacol Toxicol. 2006; 98: 275-280
- Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers.J Clin Pharmacol. 2002; 42: 1027-1030
- Lower myocardial infarction risk amongst current users of non-aspirin nonsteroidal anti-inflammatory medications [abstract].J Am Coll Cardiol. 2002; 39: 318A
- Parsing an enigma: the pharmacodynamics of aspirin resistance.Lancet. 2003; 361: 573-574
- Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study.Lancet. 2002; 359: 118-123
- Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.J Am Coll Cardiol. 2005; 45: 1295-1301
- A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385.J Biol Chem. 2003; 278: 45763-45769
- Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk.J Pain Palliat Care Pharmacother. 2005; 19: 83-97
- A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.Circulation. 2008; 118: 1894-1909
- Risk of death or reinfarction associated with use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.Circulation. 2006; 113: 2906-2913
- Complications of the COX-2 inhibitors parecoxib and celecoxib after cardiac surgery.N Engl J Med. 2005; 352: 1081-1091
- Outcomes in hypertensive patients at high CV risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.Lancet. 2004; 363: 2022-2031
- Nonnarcotic analgesics and hypertension.Am J Cardiol. 2006; 97: 10E-16E
- Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis.Ann Intern Med. 1994; 121: 289-300
- A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure.Arch Intern Med. 1993; 153: 477-484
- Cardiovascular effects of the cyclooxygenase inhibitors.Hypertension. 2007; 49: 408-418
- Selective COX-2 inhibition improves endothelial function in coronary artery disease.Circulation. 2003; 107: 405-409
- NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland.Eur Heart J. 2006; 27: 1657-1663
- Standards of medical care for patients with diabetes mellitus (position statement).Diabetes Care. 2001; 24: S33-S43
- Preserving renal function in adults with hypertension and diabetes: a consensus approach.Am J Kidney Dis. 2000; 36: 646-661
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.BMJ. 2002; 324: 71-86
- Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin.Am J Gastroenterol. 2000; 95: 2218-2224
- Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.Lancet. 2007; 369: 1621-1626
- Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?.Arthritis Rheum. 2007; 57: 748-755
- Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema?.Ther Adv Cardiovasc Dis. 2008; 2: 53-66
- Association of selective and conventional nonsteroidal antiiflammatory drugs with acute renal failure: a population-based, nested case-control study.Am J Epidemiol. 2006; 164: 881-889
- Aging and the kidney.J Am Soc Nephrol. 1996; 7: 1106-1122
- What do we know about communicating risk?.Arthritis Res Ther. 2005; 10 (Accessed on April 28): R20
- Summing the risk of NSAID therapy.Lancet. 2007; 369: 1580-1581
- Aspirin for primary prevention of coronary events.N Engl J Med. 2002; 346: 1468
- Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?.Lancet. 2007; 370: 2138-2151
- Cardiovascular risk and inhibition of cyclooxygenase.JAMA. 2006; 296: 1653-1656
- Selective cox-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.Br J Clin Pharmacol. 2008; 65: 927-934
- Nonsteroidal antiinflammatory drugs: past, present, and future.Pharmacol Res. 2009; 59: 285-289
- A randomized, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis.Ann Rheum Dis. 2005; 64: 449-456
- Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee.Arthritis Rheum. 2005; 53: 827-837
- Concomitant use of ibuprofen and aspirin: potential for attenuation of the anti-platelet effect of aspirin.(Accessed on January 4)
- Analgesic-Antipyretic and Antiinflammatory Agents and Drugs Employed in the Treatment of Gout.in: Hardman J.G. Gilman A.G. Limbird L.E. Goodman's & Gilman's The Pharmaceutical Basis of Therapeutics. 5th ed. Mcgraw-Hill, New York1996: 617-643
- A guideline for treatment and prevention of NSAID-induced ulcers.Am J Gastroenterol. 1998; 93: 2037-2046
- Recommendations for the medical management of osteoarthritis of the hip and knee; 2000 update.Arthritis Rheum. 2000; 43: 1905-1915
- Should people on aspirin avoid ibuprofen?.Cardiol in Review. 2004; 12: 174-176
- Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers.Clin Ther. 2005; 27: 185-191
- Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study.BMJ. 2003; 327: 1322-1333
- Nonsteroidal antiinflammatory drugs and the risk of myocardialinfarction in the general population.Circulation. 2004; 109: 3000-3006
- Anti-inflammatory drugs are associated with a decreased risk of recurrent acute myocardial infarction in patients on aspirin.Arthritis Rheum. 2002; 46 (Abstract): S617
- Use of Aspirin and Ibuprofen Compared With Aspirin Alone and the Risk of Myocardial Infarction.Arch Intern Med. 2004; 164: 852-856
- Effect of ibuprofen on cardioprotective effect of aspirin.Lancet. 2003; 361: 573-574
- Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs.Circulation. 2003; 108: 1191-1195
- The effects of nonselective non-aspirin non-steroidal anti inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin.J Am Coll Cardiol. 2004; 43: 985-990
Article Info
Identification
Copyright
© 2010 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
